NSE: AJANTPHARM | BSE: 532331

Expensive Performer

Download real time

2576.85 38.60 (1.52%)

26.06% Fall from 52W High

95,627 NSE+BSE Volume

NSE 17 Mar, 2025 3:31 PM (IST)

32,188

Market Cap

High in industry

0.4

Beta 1Year

Very Low volatility

Ajanta Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AJANTPHARM, BSE:532331 Ajanta Pharma Ltd.

Search Inside the pdf :

Ajanta Pharma Ltd.

31 Jan 2025

2576.85

1.52%

Ajanta Pharma (SELL): Entering newer therapies to result in higher costs

Sell: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

AJP reported in-line earnings, sales were 3.6% below estimates, while EBITDA/PAT reported 1%/3% above our estimates

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

30 Jan 2025

2576.85

1.52%

India/Asia drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered a marginally better-than-expected performance in 3QFY25. It has continued to outperform in the Domestic Formulation (DF) market during this quarter.

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

11 Dec 2024

2576.85

1.52%

Ajanta Pharma (SELL): No incremental triggers; valuation expensive

Sell: Ajanta Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

At our virtual conference AJP said it is not looking to venture into newer therapies in India in the next 1-2 years due to hefty valuations

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

11 Nov 2024

2576.85

1.52%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Ajanta Pharma Ltd. is trading below all available SMAs

Ajanta Pharma Ltd.

28 Oct 2024

2576.85

1.52%

Branded generics drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered in-line performance in 2QFY25. Asia/Africa (47% of sales) grew strongly at 32% YoY in 2QFY25 due to superior execution and partly on the low base of the past year.

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

31 Jul 2024

2576.85

1.52%

Ajanta Pharma

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

30 Jul 2024

2576.85

1.52%

Branded generics drive earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered better-than-expected 1QFY25 performance, led by a superior show in the branded Africa segment, lower raw material costs, and controlled other expenses.

Ajanta Pharma Ltd. has an average target of 2987.67 from 3 brokers.

Ajanta Pharma Ltd.

03 May 2024

2576.85

1.52%

Ajanta Pharma

Buy: Ajanta Pharma Ltd.

Target

ICICI Direct

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

03 May 2024

2576.85

1.52%

Ajanta Pharma (BUY): Strong margins; growth momentum to continue

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Strong quarter with EBITDA/PAT beat of 8% each, led by reduction in API prices, logistics costs and reduced intensity of US price erosion

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

02 May 2024

2576.85

1.52%

Higher opex leads to EBITDA/PAT miss

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered in-line sales in 4QFY24. However, EBITDA/PAT
came in lower than our expectations, due to higher opex and higher tax
outgo. AJP continued to outperform the industry in domestic formulation
(DF) and Asia market. The performance is expected to improve in the Africa
branded generics market going forward.

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Is Ajanta Pharma Ltd. worth buying?

186 Votes:

Buy 76.88%

Sell 16.13%

Hold 6.99%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf